Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210653 | 0.83 | L3MBTL1 (0.50) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL210654 | 0.83 | L3MBTL1 (0.50) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL4859584 | 0.82 | NPSR1 (0.47) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL1002114 | 0.82 | NPSR1 (0.47) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL4864100 | 0.82 | NPSR1 (0.48) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL6318931 | 0.77 | PPARA (0.52) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL1374797 | 0.77 | PPARA (0.52) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL1374794 | 0.77 | PPARA (0.52) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL24323788 | 0.76 | CA1 (0.50) | L3MBTL1PPARANPSR1CTSSPPARG | |
| SCHEMBL7053417 | 0.76 | CA1 (0.50) | L3MBTL1PPARANPSR1CTSSPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790836-B2 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1258490-B1 | PROCESS FOR PREPARING INDOLOPYRROLOCARBAZOLE DERIVATIVES, INTERMEDIATES THEREOF, AND PREPARATION PROCESS OF THE INTERMEDIATES | BANYU PHARMA CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030060621-A1 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258490-A1 | PROCESS FOR PREPARING INDOLOPYRROLOCARBAZOLE DERIVATIVES, INTERMEDIATES THEREFOR, AND PREPARATION PROCESS OF THE INTERMEDIATES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060621-A1 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | WEE1, CYP4B1, CYP3A4 | L3MBTL1 3818/4885PPARA 2793/4885NPSR1 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.